Andy is Managing Director and CEO of Section 32, a venture capital fund investing at the frontiers of technology.
Prior to Section 32, Andy was in leadership roles at Alphabet, including at X (previously GoogleX) and Verily (previously Google Life Sciences). At GoogleX, Andy worked with a variety of projects across robotics, quantum computing, machine learning, artificial intelligence, and other technology disciplines. He played a role in the spin out of the robotics and quantum computing teams and continues to serve as an advisor to various teams at X.
At Verily, Andy was the Global Head of Business and Corporate Development and a member of the executive leadership team. His team executed go-to-market campaigns for a wide range of next-generation healthcare technologies building creative and pioneering partnerships, collaborations and joint ventures with some of the world’s top companies. Andy’s efforts directly contributed to Verily’s rapid scale up, multi-billion dollar financing rounds and Verily’s efforts to address the opioid and Covid-19 epidemics. Andy also co-founded the Verily Ventures program to make early-stage venture investments. Under his stewardship, the program generated top-tier venture returns.
Prior to Google, Andy helped build and scale two businesses. One firm was seeded by Stanford University’s Endowment, which was successfully acquired while the second — a health-care oriented private equity firm — is growing and active in San Francisco. He started his career at RBC Ventures at a fund which was a part of the DFJ Global Network.
Andy is a patented inventor with an Undergraduate Degree in Biochemical Engineering from McGill University and a Master in Biomedical Engineering from Cornell University. He also holds the Chartered Financial Analyst designation.